(Total Views: 779)
Posted On: 03/16/2024 10:59:44 AM
Post# of 148892
What really confused me on the Data Safety board recommending go from 28, to 42 day observation, was Dr. Frederick Hayden.
I had e-mailed this to Cytodyn @ the time & posted:
Sent: Friday, May 14, 2021, 08:59:43 PM PDT
Subject: Fredrick DSMB --- Cytodyn
https://www.thelancet.com/journals/lancet/art...lltext#%20
"FGH is a member of the Data Safety and Monitoring Board for a clinical trial funded by Cytodyn, Inc,
with fees paid to the University of Virginia School of Medicine"
My69z2 hours ago
Frederick G Hayden
"Dr. Frederick Hayden is a non compensated consultant to Gilead Sciences"
May 2020:
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial ----
This 10k patient, Severe/Critical China study lists Frederick G Hayden.
Oct. 2020, RECOVERY Collaborative Group report on Lopinavir–ritonavir.
This is AbbVie’s HIV drug Kaletra & where i found the above Dr. Hayden references to Cytodyn.
Would like to know what justified going to 42 days, when we did not have many deaths outside of Day 28.
_____________
In 2024, remember before the safety report, Cytodyn mentioned wanting a trial comparison to Remdesivir.
Dr. Hayden would have of course already seen LL's performance, in comparison to the 10k chinese data. My bet is, he already knew Remdesivir large trial had nothing like LL's 14 day performance.
Same with pushing to 28 days.
Then add observing out to 42 days.
Yet dosing stop @ 2 within 14 days.
One thing to not like the non-medical, scamming CEO, Vs letting the molecule produce data.
Just all pretty ironic, Gilead's consultant, did not recuse himself. Then again, it was also posted @ the time board members are never known.
Dr. J knows all the past plus & negatives, has always shot us straight & loving the new chapter he said Cytodyn has started.
The world needs LL & LL is finally backed by qualifing management.
I had e-mailed this to Cytodyn @ the time & posted:
Sent: Friday, May 14, 2021, 08:59:43 PM PDT
Subject: Fredrick DSMB --- Cytodyn
https://www.thelancet.com/journals/lancet/art...lltext#%20
"FGH is a member of the Data Safety and Monitoring Board for a clinical trial funded by Cytodyn, Inc,
with fees paid to the University of Virginia School of Medicine"
My69z2 hours ago
Frederick G Hayden
"Dr. Frederick Hayden is a non compensated consultant to Gilead Sciences"
May 2020:
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial ----
This 10k patient, Severe/Critical China study lists Frederick G Hayden.
Oct. 2020, RECOVERY Collaborative Group report on Lopinavir–ritonavir.
This is AbbVie’s HIV drug Kaletra & where i found the above Dr. Hayden references to Cytodyn.
Would like to know what justified going to 42 days, when we did not have many deaths outside of Day 28.
_____________
In 2024, remember before the safety report, Cytodyn mentioned wanting a trial comparison to Remdesivir.
Dr. Hayden would have of course already seen LL's performance, in comparison to the 10k chinese data. My bet is, he already knew Remdesivir large trial had nothing like LL's 14 day performance.
Same with pushing to 28 days.
Then add observing out to 42 days.
Yet dosing stop @ 2 within 14 days.
One thing to not like the non-medical, scamming CEO, Vs letting the molecule produce data.
Just all pretty ironic, Gilead's consultant, did not recuse himself. Then again, it was also posted @ the time board members are never known.
Dr. J knows all the past plus & negatives, has always shot us straight & loving the new chapter he said Cytodyn has started.
The world needs LL & LL is finally backed by qualifing management.
(16)
(0)Scroll down for more posts ▼
